Creative Biolabs offers a series of AI-based antibody screening services based on the prediction of antibody-antigen binding. We offer a unique way to find rare antibody clusters and get more candidate antibody sequences by augmenting our data-driven AI screening services.
Every year 2500 discovery projects fail to find strong binders with biological effects because of insufficient diversity: in vitro screening starts with a limited set of antibodies and 90% of the binders are lost due to limitations of the process. New antibody panels generated by AI are a source of candidates with new binding modalities and potentially new therapeutic modes-of-action. Typically, AI screening can generate 10 times more antibody sequence clusters than a laboratory-based approach alone, resulting in increased diversity of antibody sequences and target epitope binding which equals greater opportunity to optimize receptor agonism.
Fig.1 Artificial intelligence for antibody screening and discovery.
The AI-based approach has been proved its significant role in antibody design, screening, and testing. Combined with artificial intelligence, big data, and machine learning, Creative Biolabs integrated the published data and different kinds of AI models to train our bespoke algorithm, through which, we can identify the interaction between potential antibodies and disease states, predict antibody-antigen binding, create optimized antibody sequences, accelerate antibody drug discovery. For the same target antigen, our in silico screening can be conducted by AI models to identify a safe, suitable, and effective candidate to reduce the delivery time.
Creative Biolabs is specialized in designing and performing high-quality custom AI-based antibody screening assays, with different formats, endpoints, parameters, to satisfy any specific requirement at a most competitive price. For more detailed information, please feel free to contact us or directly sent us an inquiry.
Follow us on:
Copyright © 2024 Creative Biolabs. All Rights Reserved.
